We have established a cohort of 64 Natural Viral Suppressors (NVS) (similar to Elite Controllers/ Elite Suppressors), 30 of which have chronic hepatitis C virus (HCV). We investigated T-cell phenotypic changes in association with HCV infection. NVS without HCV and normal controls had similar T-cell phenotypes. However, NVS with HCV had lower naive cell proportions (CD4 and CD8) compared with NVS without HCV (P U 0.0008 and P U 0.02) or normal controls (P U 0.0163 and P U 0.017). These results and previously reported data suggest that HCV coinfection increases immune activation and T-cell disturbances. Any associated T-cell functional changes or potential clinical consequences need further study.
The Natural Viral Suppressors (NVS) cohort is comprised of HIV-infected patients with the ability to suppress HIV-1 to undetectable levels in the absence of therapy [1] [2] [3] [4] . We have established a cohort of 64 NVS patients, of which 46.9% have chronic hepatitis C virus (HCV) infection (positive PCR for HCV). We previously reported that, within this NVS cohort, patients with HCV infection had lower CD4 cell counts, CD4 cell count percentages, CD4/CD8 ratio, and higher levels of immune activation than NVS without HCV infection [4] . In this study, we further investigated whether there are specific phenotypic immunological deficits associated with HCV infection in this cohort.
The NVS cohort and controls (HIV/HCV negative individuals, HCV monoinfected patients, and non-NVS HIV and HIV/HCV coinfected) have been described in detail elsewhere [1] [2] [3] [4] . Briefly, after informed consent was obtained, NVS patients have demonstrated viral loads less than 400 copies/ml for a 2-year time period without antiretroviral therapy. Flow cytomtery was performed by using FACSCalibur flow (BD Biosciences, San Jose, California, USA). Peripheral blood mononuclear cells were stained with either CD4 (APC) or CD8 (APC), and CD3 (PerCP), CD45RA (FITC), and CCR7 (PE) and optimized according to the experiment. Data was analyzed by using FlowJo software (Ashland, Oregon, USA). For data with normal distribution Student's t test was performed; otherwise, the Mann-Whitney test was used. All P values were two-tailed and considered significant if less than 0.05.
T-cell subsets were measured in the NVS with HCV infection (n ¼ 10), NVS without HCV infection (n ¼ 9), HIV negative/HCV negative controls (n ¼ 8), HCV positive monoinfected (n ¼ 9), HIV positive monoinfected (n ¼ 8), and HIV positive/HCV positive coinfected patients (n ¼ 5) ( Fig. 1 ). NVS without HCV had a trend toward greater CD4 and CD8 cell naive cell proportions than the normal controls who are HCV and HIV negative (P ¼ 0.1 and P ¼ 0.24, respectively). In contrast, NVS with HCV had lower naive cell proportions (CD4 and CD8) compared with NVS without HCV (P ¼ 0.0008 and P ¼ 0.02, respectively) or normal controls (P ¼ 0.0163 and P ¼ 0.017, respectively). NVS with HCV also had higher effector memory cell proportions (CD4 and CD8) compared with NVS without HCV (P ¼ 0.003 and P ¼ 0.01, respectively). Within the NVS, there was no significant difference in central memory or terminally differentiated cell compartments in relation to HCV infection. Interestingly, the naive CD4 cell population was also lower in our HIV/HCV controls compared with HIV monoinfected controls (P ¼ 0.045).
The clinical consequences of altered T-cell subsets, specifically reduction in the proportion of naive T cells, are not well characterized in the context of HCV infection. We evaluated clinical outcomes in the NVS group based on HCV infection. Compared with NVS without HCV, NVS with HCV have higher prevalence rates of cancer (23.3% vs. 8.8%), death (16.7% vs. 5.9%), and coronary artery disease (6.7% vs. 0%) after HIV-1 diagnosis. Of note, none of the deaths or cancers were directly attributable to HCV. The number of events was too small to carry out meaningful statistical analysis.
In this study, we demonstrate further immunological deficits as well as possible differences in clinical outcome based on the presence or absence of HCV coinfection. Proportions of CD4 and CD8 naive cells were similar in NVS without HCV and normal controls, suggesting preservation of these subsets in NVS without HCV. NVS with HCV had lower naive cell proportions (CD4 and CD8) compared with NVS without HCV or normal controls, suggesting a loss of this subset in association with dual HIV/HCV infection. A reduced number of naive T cells is a hallmark of HIV infection [5] [6] [7] , however, there is only one report of HCV causing a reduction of naive T-cell populations [8] . In this study we also note lower CD4 naive cell proportions in HIV/HCV controls compared with HIV monoinfected controls. Higher levels of apoptosis of naive CD4 and CD8 cells in HIV/HCV infection, as reported by Nunez et al. [9] , could explain our findings of immune activation, lower CD4 cells, and lower naive cells.
Taken together, the most likely explanation for the above data is that HCVaffects the course of HIV infection in the NVS. HCV has not been reported to cause a decreased CD4 cell count or increased immune activation in HCV monoinfected individuals [10] . However, we hypothesize 
that, in the setting of HIV infection, HCV coinfection can increase immune activation, and cause T-cell disturbances (decreased CD4 cell count, decreased naive T cells, increased effector T cells). This interaction between HIV and HCVas it pertains to T-cell dynamics has still not been consistently demonstrated before. Recently, HIV/HCV coinfected patients have been shown to have increased levels of CD8 activation compared with HIV monoinfected patients [11] [12] [13] , with HCV treatment leading to a decrease in immune activation [11] .
Age and duration of HIV infection need to be considered in interpreting our data. NVS are both aging (median age 53) and have carried HIV infection for decades (median year of HIV diagnosis 1995), although these were equally matched in the NVS HCV positive and negative groups. Aging is known to affect the normal immune system [14] [15] [16] , and thus it is entirely plausible that the presence of two agents known to cause immune changes/ deficits could lead to worse immunologic and clinical outcomes. One reason this may have not been noted before is that the median year of HIV diagnosis of the NVS predates the HAARTera, and these defects may not be seen in HAART-infected cohorts for several more years.
In conclusion, NVS patients with chronic HCV infection have lower proportions of naive CD4 and CD8 cells, and elevated effector memory CD4 and CD8 cells. Lower proportions of naive CD4 cells were noted in the HIV/HCV controls (non-NVS) when compared with the HIV monoinfected controls. There appears to be higher rates of clinical complications (coronary artery disease, cancer, and death) in the NVS with chronic HCV infection compared to those without HCV infection. The data suggest that, in the NVS cohort (elite controllers) HCV coinfection detrimentally alters the natural history of HIV infection. Further studies will be needed to evaluate potential functional deficits associated with HCV coinfection, and if HCV treatment leads to lower immune activation levels and rise in CD4 cell counts in these patients. This preliminary study was performed to assess the neutralization activity of anti-MPER-secretory IgA (SIgA) from parotid saliva in 88 HIVR patients, in five exposed seronegative (ESN) and in five seronegative volunteers. 48.9% of the HIVR patients and 100% of ESN patients showed antigp41 SIgA. 25 .6% of anti-MPER SIgA from HIVR patients and 100% from ESN patients neutralized efficiently HIV-1 primary isolate SF162 (IC 50). The neutralization activity is maintained for much lower concentrations in ESN than in HIVR secretions.
Antibodies of the IgA class are major components of the immunological defenses present at mucosal surfaces. Ninety per cent of sexual transmission of HIV occurs across the mucosa. Secretory IgA (SIgA) can protect the organism against HIV infection by distinct mechanisms such as direct neutralization, [1] [2] [3] [4] [5] [6] , inhibition of transcytosis [4, [7] [8] [9] [10] , intracellular virus neutralization [11, 12] or preventing HIV entry through the epithelial lumen [8] .
SIgA have been demonstrated to neutralize primary isolates of HIV-1 in infected patients but also in exposed seronegative (ESN) patients [13] [14] [15] [16] [17] . These neutralizing antibodies are directed against different key regions on the gp160 surface such as the superantigenic site on gp120 and the CD4 binding site [18] [19] [20] . We have previously shown that parotid saliva from ESN contains neutralizing V1/V2specific IgA [21, 22] . Functional neutralizing IgA from ESN that target the features QARILAVERY and QARILAV, epitopes within the coiled-coil region of gp41, have been previously described [2, 6] . Immunization of macaques with virosomes containing this peptide leads to protection by producing gp41-specific SIgA in genital secretions [23] . The QARILAVERY and QARILAV patterns correspond to the immunosuppressive epitope on gp41 [24] but this fact is not discussed in terms of the neutralizing effect of the SIgA antibodies directed against them [2, 6] . MPER is a highly conserved region on gp41 protein involved in the early stages of attachment and infection of HIV-1 [25] . This region includes the epitopes of well described human IgG neutralizing MAbs as 2F5, 4E10, Z13 [26] [27] [28] and a recently described antibody, 10E8, which is the broadest and most potent antibody that has been observed so far [29] . The involvement of a specific-MPER SIgA blocking transcytosis by recognition of the neutralizing epitope ELDKWA has been demonstrated [30] . Until now, few studies have described the role of natural mucosal anti-MPER SIgA in HIVþ patients and in ESN patients and their involvement in the protection by neutralization of HIV.
Parotid saliva was sampled from 88 HIVþ patients, from five ESN patients (14 women and 79 men) from the Department of Infectious Diseases, University Hospital, Saint-Etienne, France and from five HIV-patients. The purification of SIgA was performed on parotid saliva to avoid contamination by serum antibodies that can be present in total saliva [17, 21] . Residual IgG and IgM were depleted from parotid saliva by affinity using Dynabeads Protein G (Life Technologies, Paisley, UK) (data not shown). The SIgA directed to conformational gp41 was detected by immunofluorescence with gp41 transfected HEK 293 cells (HEK 293gp41 MSD ) [31] (Sup. Figure S1 , http://links.lww.com/QAD/A366). This strategy has the advantage to select only SIgA recognizing preferentially conformational and glycosylated epitopes instead of linear epitopes using synthetic peptides [32, 33] . 2F5, 3D6 and 4E10 mAb (Polymun Scientific, Vienna, Austria) which bound to HEK 293gp41 MSD were used as positive controls. 48.9% (43/88) of the HIVþ patients and 100% (5/5) of the ESN patients presented SIgA that bound specifically to the transfected cells. From saliva with antigp41 SIgA, the MPER-specific SIgA were purified using affinity with magnetic beads (Dynabeads) engrafted with 6XHistagged MPER peptide (NT-659 ELLELDK-WASLWNWFNITNWLWYIK-6xH 683 CT; Millegen, Toulouse, France). A control western blot assay was performed to confirm the integrity of the purified SIgA (Sup. Figure S2 , http://links.lww.com/QAD/A366). The capacity of total antigp41 saliva diluted to 1/100 [SIgA median concentration was 29 ng/ml in HIVþand 45 ng/ml in ESN] and of anti-MPER SIgA to inhibit the infection of activated PBMC by a SF162 primary isolate (NIH AIDS Research and Reference Reagent) were tested with a 100 TCID50 dose [16] . The percentage of neutralization was calculated as the reduction of p24 production obtained after infection. Gp41-specific SIgA were neutralizing with an IC50 and IC80, respectively, in 58.1% (25/43) and in 25.6% (11/43) of HIVþ patients versus 100% (5/5) and 60% (3/5) of ESN and 0% (0/5) of HIVÀ individuals (Fig. 1a) . The anti-MPER SIgA were neutralizing in 41.9% (18/43) and 25.6% (11/43) of the HIVþ patients versus 100% (5/5) and 60% (3/5) of ESN and 0% (0/5) of HIVÀ ( Fig. 1b) . After quantification of SIgA in selected saliva by ELISA technique [34] , the dose response with serially diluted antibody was studied in five HIVþ patients and in the five ESN patients. The neutralizing activity of antigp41 SIgA from the HIVþ patients decreased progressively from 0.24 to 0.04 mg/ml; by contrast, in the ESN, antigp41 SIgA values observed were significantly higher than IC50 until the lowest concentration tested (0.02 mg/ml) ( Fig. 1c and d) .
The MPER segment of the gp41 expressed on the surface of HIV particles plays an important role in the fusion of viral and cellular membranes during the infection process with HIV-1 [35, 36] . The anti-MPER SIgA from the parotid saliva of ESN patients has a high neutralization activity even at very low concentrations (pg/ml) while the most neutralizing monoclonal IgGs, directed to MPER, 4E10 and 2F5, neutralized SF162 at 1 and 1.4 mg/ml, respectively, for the IC80 and 720 and 556.4 ng/ml, respectively, for the IC50 (Sup. Figure S3 , http://links. lww.com/QAD/A366).
Neutralization assays will need to be performed with other strains to confirm these results but the scarcity of ESN patients and the low volume of parotid saliva samples limited this study. Several data showed that the ESN state depends on various factors such as genetic polymorphism in the regulatory region of the CCR5 or CCR2 genes, the intensity of the mannose-binding lectins or of DC-sign expression [37] . The activation of CD8 þ lymphocytes and the secretion profile of CC-chemokines in CD4 þ lymphocytes can be involved in reducing HIV susceptibility in ESN patients. Concerning mucosal immunity in ESN patients, studies are very controversial as the absence [38, 39] or the presence of neutralizing SIgA was described [1, 10, 40] and, in some of them, antigp41 SIgA was demonstrated [7, 23, 30] . This preliminary study shows the neutralizing effect of parotid salivary SIgA to MPER in ESN patients suggesting that they could be associated with protection, even if a more important cohort has to be recruited to gather further data and to confirm our observations. Successful vaccine development will need to stimulate a mucosal immune response and thus the factors that prevent HIV infection in ESN state patients/ individuals.
